hVIVO specializes in conducting human challenge trials, a critical component of vaccine and antiviral development. This segment focuses on testing infectious and respiratory disease products through clinical trials. The company utilizes a range of human challenge study models for conditions such as RSV, flu, asthma, and COPD, and is developing a COVID-19 human challenge study model. hVIVO's research and development activities include the design and execution of these trials, as well as the analysis of clinical, immunological, virological, and digital biomarkers. The company's expertise in this area provides valuable data for pharmaceutical and biotechnology companies, accelerating the development of new treatments and vaccines. hVIVO's market position is strong due to its leadership in human challenge trials, offering a unique service that can significantly reduce the time and cost of drug development. Future opportunities include expanding the range of challenge models and leveraging data analytics to improve trial efficiency and outcomes. Regulatory and clinical aspects are central to this segment, with hVIVO adhering to strict guidelines to ensure patient safety and data integrity. Partnerships with pharmaceutical companies and government organizations are key to this segment's success.

This segment focuses on the development and application of the Disease in Motion platform, a database of infectious disease progression data. This platform includes unique datasets such as clinical, immunological, virological, and digital (wearable) biomarkers. The technologies and methodologies used include data collection, analysis, and interpretation, with a focus on providing insights into disease progression and treatment efficacy. The therapeutic areas covered include a wide range of infectious diseases, with the potential to expand into other areas. The patient impact is significant, as the platform can help to improve the understanding of diseases and accelerate the development of new treatments. hVIVO's market positioning is enhanced by its ability to provide valuable data to big technology, wearables, pharma, and biotech companies. Future opportunities include expanding the platform's data sets and applications, as well as integrating with other data sources. Regulatory and clinical aspects are important, with a focus on data privacy and security. Partnerships with technology and pharmaceutical companies are key to this segment's growth.

This segment provides a range of services to European pharmaceutical clients, including biometry, data management, and statistics. It also offers drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing. The research and development activities include the development of new methodologies for data analysis and the improvement of drug development processes. The technologies and methodologies used include statistical analysis, data management systems, and regulatory expertise. The therapeutic areas covered include a wide range of pharmaceutical products. The patient impact is significant, as these services help to accelerate the development of new drugs and improve patient outcomes. hVIVO's market positioning is strong due to its expertise in providing these services to European clients. Future opportunities include expanding the range of services offered and entering new markets. Regulatory and clinical aspects are central to this segment, with a focus on compliance with European regulations. Partnerships with pharmaceutical companies are key to this segment's success.